Tumours might be sensitized to immune therapy by COVID mRNA vaccines

Commercially available mRNA vaccines against COVID have been shown to train patients’ immune systems to kill cancer cells. Combining these vaccines with standard-of-care immune therapy overwhelms tumour defences and is associated with improved survival, both in animal models and in large cohorts of people with cancer. COVID vaccines enhance the antitumour response of immunotherapies and result in increased patient survival.